FUNDAMENTALS · Fundamentals · US Healthcare

Viridian Therapeutics (VRDN) Fundamentals 2026 — Revenue Analysis | SniperIQ

Viridian Therapeutics (VRDN) is a US-listed Healthcare company in Biotechnology with a market capitalization of

.7B, trading at
8.90 on the NASDAQ. This SniperIQ fundamentals page covers Viridian Therapeutics's valuation, profitability (net margin -508.5%), revenue ($71M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
.7B
Net Margin-508.5%
Revenue (FY25)$71M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Viridian Therapeutics's market cap?

Viridian Therapeutics (VRDN) has a market capitalization of approximately

.7B, trading at
8.90 on the NASDAQ. Market cap moves with the live share price.

What is Viridian Therapeutics's P/E ratio?

Viridian Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Viridian Therapeutics?

Viridian Therapeutics runs a net profit margin of -508.5%, a gross margin of 99.4%, and an operating margin of -543.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Viridian Therapeutics generate?

Viridian Therapeutics reported revenue of $71M for fiscal year 2025, with net income of -

43M and earnings per share (EPS) of -3.32. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Viridian Therapeutics pay a dividend?

Viridian Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Viridian Therapeutics financially healthy?

Viridian Therapeutics carries a debt-to-equity ratio of 0.08x and a current ratio of 15.15x, with a market beta of 0.90. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Viridian Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Viridian Therapeutics (VRDN) the key facts are: market cap

.7B, revenue $71M, 52-week range 13.18-34.29. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Viridian Therapeutics's full fundamentals live

Get Viridian Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Healthcare Services Group (HCSG) fundamentals · Synbio Tech (1295) fundamentals · Fortrea Holdings (FTRE) fundamentals · Palvella Therapeutics (PVLA) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons